Altria is well-positioned to enter the U.S. cannabis market through its 42% stake in Cronos Group, which recently posted record Q3 results and is expanding internationally. Meanwhile, Altria's core tobacco business remains strong, with a 2.8% rise in adjusted EPS for Q2 2026 and a 4.7% dividend increase. The potential rescheduling of adult-use cannabis in the U.S. could significantly boost valuations for both Altria and Cronos, making this a key investment thesis. The outlook depends on regulatory changes that could unlock substantial growth opportunities.
Altria Group Inc trades at USD 76.07 with a 5.83% dividend yield on Pluang as of Nov 09, 2026 19:41 WIB, showing a slight 0.07% decline in one day. Cronos Group Inc is priced at USD 3.56, down 1.39% on the same date, reflecting shorter typical hold times of 23 days compared to Altria's 157 days. This trading activity occurs as regulatory changes could unlock growth potential for both companies in the cannabis sector.
